0.9598
price down icon1.04%   -0.0101
after-market After Hours: .99 0.0302 +3.15%
loading
Unity Biotechnology Inc stock is traded at $0.9598, with a volume of 120.48K. It is down -1.04% in the last 24 hours and down -17.97% over the past month. Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities unique to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases. Its drug candidates include, UBX1325 is being developed for age-related diseases of the eye, including diabetic macular edema, or DME, UBX2089, which is a circulating hormone primarily produced in the kidneys and choroid plexus of the brain, which is being researched for multiple neurology indications, and UBX2050.
See More
Previous Close:
$0.9699
Open:
$0.9505
24h Volume:
120.48K
Relative Volume:
1.85
Market Cap:
$16.17M
Revenue:
-
Net Income/Loss:
$-52.53M
P/E Ratio:
-0.2418
EPS:
-3.97
Net Cash Flow:
$-39.93M
1W Performance:
-14.30%
1M Performance:
-17.97%
6M Performance:
-23.52%
1Y Performance:
-42.53%
1-Day Range:
Value
$0.9468
$0.995
1-Week Range:
Value
$0.9468
$1.12
52-Week Range:
Value
$0.9468
$2.02

Unity Biotechnology Inc Stock (UBX) Company Profile

Name
Name
Unity Biotechnology Inc
Name
Phone
(650) 416-1192
Name
Address
285 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA
Name
Employee
19
Name
Twitter
@unitybiotech
Name
Next Earnings Date
2024-11-11
Name
Latest SEC Filings
Name
UBX's Discussions on Twitter

Compare UBX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
UBX
Unity Biotechnology Inc
0.9598 16.17M 0 -52.53M -39.93M -3.66
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
397.27 102.31B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
701.85 77.13B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
623.82 37.30B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
245.44 31.66B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
113.08 27.11B 3.30B -501.07M 1.03B -2.1146

Unity Biotechnology Inc Stock (UBX) Upgrades & Downgrades

Date Action Analyst Rating Change
Aug-22-24 Initiated Rodman & Renshaw Buy
Nov-16-23 Upgrade Wedbush Neutral → Outperform
Jan-04-22 Upgrade ROTH Capital Neutral → Buy
Nov-10-21 Upgrade Mizuho Neutral → Buy
Jun-28-21 Upgrade Citigroup Sell → Buy
Jun-07-21 Initiated H.C. Wainwright Buy
Feb-16-21 Downgrade Citigroup Neutral → Sell
Aug-18-20 Downgrade Citigroup Buy → Neutral
Aug-18-20 Downgrade Mizuho Buy → Neutral
Aug-18-20 Downgrade Morgan Stanley Overweight → Equal-Weight
Aug-17-20 Downgrade ROTH Capital Buy → Neutral
Jul-28-20 Initiated ROTH Capital Buy
Dec-12-19 Initiated Cantor Fitzgerald Overweight
Mar-07-19 Initiated Cantor Fitzgerald Overweight
Sep-07-18 Initiated Mizuho Buy
May-29-18 Initiated Citigroup Buy
May-29-18 Initiated Goldman Neutral
May-29-18 Initiated Morgan Stanley Overweight
View All

Unity Biotechnology Inc Stock (UBX) Latest News

pulisher
Dec 20, 2024

Unity Biotechnology stock hits 52-week low at $0.95 - Investing.com

Dec 20, 2024
pulisher
Dec 18, 2024

Unity Biotechnology (NASDAQ:UBX) Trading Down 5.6% – What’s Next? - Defense World

Dec 18, 2024
pulisher
Dec 12, 2024

Unity Biotechnology stock hits 52-week low at $1.1 - Investing.com

Dec 12, 2024
pulisher
Dec 12, 2024

Unity Biotechnology stock hits 52-week low at $1.1 By Investing.com - Investing.com UK

Dec 12, 2024
pulisher
Dec 05, 2024

Unity Biotechnology stock hits 52-week low at $1.1 amid challenges - Investing.com Canada

Dec 05, 2024
pulisher
Dec 05, 2024

Unity Biotechnology (FRA:9U90) EV-to-Revenue : (As of Dec. 05, 2024) - GuruFocus.com

Dec 05, 2024
pulisher
Nov 28, 2024

Unity Biotechnology (STU:9U90) EV-to-Revenue : (As of Nov. 28, 2024) - GuruFocus.com

Nov 28, 2024
pulisher
Nov 25, 2024

Finance Watch: Adcendo Pursues Proof-Of-Concept With $135m Series B Round - Citeline

Nov 25, 2024
pulisher
Nov 25, 2024

Unity Biotechnology (FRA:9U90) Price-to-Operating-Cash-Flow : (As of Nov. 25, 2024) - GuruFocus.com

Nov 25, 2024
pulisher
Nov 19, 2024

Frazier Life Sciences Appoints John Smither and Jim Williams as Senior Advisors - BioSpace

Nov 19, 2024
pulisher
Nov 15, 2024

Alyeska Investment Group L.P.'s Strategic Acquisition in Unity B - GuruFocus.com

Nov 15, 2024
pulisher
Nov 15, 2024

Carisma Therapeutics (NASDAQ:CARM) vs. Unity Biotechnology (NASDAQ:UBX) Head-To-Head Comparison - Defense World

Nov 15, 2024
pulisher
Nov 11, 2024

Pre-market Movers: REVB, CDIO, SMLR, DWTX... - RTTNews

Nov 11, 2024
pulisher
Nov 07, 2024

Unity Biotechnology's CFO sells shares worth $175 - Investing.com India

Nov 07, 2024
pulisher
Nov 07, 2024

Unity Biotechnology's chief legal officer sells shares worth $192 - Investing.com India

Nov 07, 2024
pulisher
Nov 06, 2024

Unity Biotechnology's CFO sells shares worth $175 By Investing.com - Investing.com Canada

Nov 06, 2024
pulisher
Nov 06, 2024

Unity Biotechnology's chief legal officer sells shares worth $192 By Investing.com - Investing.com Canada

Nov 06, 2024
pulisher
Nov 06, 2024

Unity Biotechnology stock hits 52-week low at $1.15 - Investing.com

Nov 06, 2024
pulisher
Nov 05, 2024

Unity Biotechnology stock hits 52-week low at $1.15 By Investing.com - Investing.com Canada

Nov 05, 2024
pulisher
Nov 05, 2024

Is Unity Biotechnology (NASDAQ:UBX) In A Good Position To Invest In Growth? - Simply Wall St

Nov 05, 2024
pulisher
Nov 04, 2024

Unity Biotechnology Focuses on Promising DME Treatment - TipRanks

Nov 04, 2024
pulisher
Nov 04, 2024

Dyadic to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024 - The Manila Times

Nov 04, 2024
pulisher
Nov 04, 2024

UNITY Biotechnology, Inc. Reports Third Quarter 2024 Financial Results and Business Updates - GlobeNewswire

Nov 04, 2024
pulisher
Oct 22, 2024

Age-related Macular Degeneration Market Size is Set for Rapid - openPR

Oct 22, 2024
pulisher
Oct 16, 2024

Wet Age-Related Macular Degeneration Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - The Globe and Mail

Oct 16, 2024
pulisher
Oct 16, 2024

Empery Asset Management LP Acquires Shares in Tonix Pharmaceuticals - Yahoo Finance UK

Oct 16, 2024
pulisher
Oct 11, 2024

First patient dosed at the Tokyo Medical Center by Belite Bio in Phase 2/3 DRAGON II clinical trial - Ophthalmology Times

Oct 11, 2024
pulisher
Oct 09, 2024

Empery Asset Management, LP Acquires Shares in Volcon Inc - Yahoo Finance UK

Oct 09, 2024
pulisher
Oct 09, 2024

Empery Asset Management's Strategic Acquisition in Elevation Oncology - Yahoo Finance

Oct 09, 2024
pulisher
Oct 09, 2024

Empery Asset Management's Strategic Reduction in Sharps Technology Inc - Yahoo Finance

Oct 09, 2024
pulisher
Oct 03, 2024

To Reverse Aging’s Clock, Adjust the Cell’s Machinery - Genetic Engineering & Biotechnology News

Oct 03, 2024
pulisher
Sep 24, 2024

UNITY Biotechnology to Host In-Person Ophthalmology Day in New York on Tuesday, October 15, 2024 - GlobeNewswire

Sep 24, 2024
pulisher
Sep 24, 2024

Unity Biotechnology (FRA:9U90) Cash Ratio : 3.85 (As of Jun. 2024) - GuruFocus.com

Sep 24, 2024
pulisher
Sep 23, 2024

Jefferies Financial Group Boosts United Therapeutics (NASDAQ:UTHR) Price Target to $432.00 - Defense World

Sep 23, 2024
pulisher
Sep 23, 2024

Tri Locum Partners LP Makes New Investment in United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat

Sep 23, 2024
pulisher
Sep 22, 2024

Epoch Investment Partners Inc. Increases Stake in United Therapeutics Co. (NASDAQ:UTHR) - Defense World

Sep 22, 2024
pulisher
Sep 22, 2024

United Therapeutics Co. (NASDAQ:UTHR) Shares Acquired by Mercer Global Advisors Inc. ADV - Defense World

Sep 22, 2024
pulisher
Sep 22, 2024

Symmetry Investments LP Makes New Investment in United Therapeutics Co. (NASDAQ:UTHR) - Defense World

Sep 22, 2024
pulisher
Sep 22, 2024

American Century Companies Inc. Has $13.14 Million Position in United Therapeutics Co. (NASDAQ:UTHR) - Defense World

Sep 22, 2024
pulisher
Sep 21, 2024

Pacer Advisors Inc. Grows Holdings in United Therapeutics Co. (NASDAQ:UTHR) - Defense World

Sep 21, 2024
pulisher
Sep 21, 2024

Meiji Yasuda Asset Management Co Ltd. Buys 33 Shares of United Therapeutics Co. (NASDAQ:UTHR) - Defense World

Sep 21, 2024
pulisher
Sep 20, 2024

Longevity and Anti-Senescence Therapy Market Share, Size, Growth, and Forecast to 2031 - InsightAce Analytic

Sep 20, 2024
pulisher
Sep 19, 2024

Inspire Investing LLC Acquires 2,936 Shares of United Therapeutics Co. (NASDAQ:UTHR) - Defense World

Sep 19, 2024
pulisher
Sep 18, 2024

Uniti Group Inc [UNIT] stock was sold by Mudry Ronald J. at the price of US$0.11 million - Knox Daily

Sep 18, 2024
pulisher
Sep 18, 2024

1,054 Shares in United Therapeutics Co. (NASDAQ:UTHR) Bought by Choreo LLC - Defense World

Sep 18, 2024
pulisher
Sep 18, 2024

Quest Partners LLC Has $89,000 Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR) - Defense World

Sep 18, 2024
pulisher
Sep 17, 2024

Liquidia Corp faces renewed legal challenge from United Therapeutics By Investing.com - Investing.com Australia

Sep 17, 2024
pulisher
Sep 17, 2024

Meeder Advisory Services Inc. Invests $36,000 in Uniti Group Inc. (NASDAQ:UNIT) - Defense World

Sep 17, 2024
pulisher
Sep 17, 2024

Unity Software Inc. (NYSE:U) Shares Bought by Daiwa Securities Group Inc. - Defense World

Sep 17, 2024
pulisher
Sep 17, 2024

Commonwealth Equity Services LLC Has $1.16 Million Position in Unity Software Inc. (NYSE:U) - Defense World

Sep 17, 2024
pulisher
Sep 16, 2024

Court rules against United Therapeutics in Liquidia case - Investing.com India

Sep 16, 2024

Unity Biotechnology Inc Stock (UBX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Unity Biotechnology Inc Stock (UBX) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Sullivan Lynne Marie
CFO & Head of Corp. Dev.
Nov 04 '24
Sale
1.29
136
175
55,925
Nguyen Alexander Hieu
Chief Legal Officer
Nov 04 '24
Sale
1.29
149
192
24,723
Nguyen Alexander Hieu
Chief Legal Officer
Aug 02 '24
Sale
1.53
154
236
24,872
Ghosh Anirvan
Chief Executive Officer
Aug 02 '24
Sale
1.53
604
924
76,325
Sullivan Lynne Marie
CFO & Head of Corp. Dev.
Aug 02 '24
Sale
1.53
139
213
56,061
Nguyen Alexander Hieu
Chief Legal Officer
Jun 25 '24
Sale
1.40
78
109
25,026
Ghosh Anirvan
Chief Executive Officer
Jun 25 '24
Sale
1.40
1,214
1,700
76,929
Sullivan Lynne Marie
CFO & Head of Corp. Dev.
Jun 25 '24
Sale
1.40
324
454
32,685
Ghosh Anirvan
Chief Executive Officer
May 02 '24
Sale
1.55
603
935
78,143
Ghosh Anirvan
Chief Executive Officer
Feb 02 '24
Sale
1.71
680
1,163
78,746
$17.87
price down icon 2.88%
$68.84
price up icon 2.65%
$39.39
price down icon 0.43%
$359.58
price down icon 0.16%
$176.50
price up icon 1.02%
$113.08
price up icon 1.56%
Cap:     |  Volume (24h):